Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 35, Issue 12, Pages 1173-1188
Publisher
Wiley
Online
2015-12-19
DOI
10.1002/phar.1671
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
- (2017) M. Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
- (2015) David H. Vesole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- The role of epigenetics in the biology of multiple myeloma
- (2014) K Dimopoulos et al. Blood Cancer Journal
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
- (2013) James R. Berenson et al. ANNALS OF HEMATOLOGY
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
- (2013) Marian Iwamoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy
- (2013) Jonathan L. Kaufman et al. Clinical Lymphoma Myeloma & Leukemia
- Histone deacetylase inhibitors in the treatment for multiple myeloma
- (2013) Teru Hideshima et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
- (2013) D J DeAngelo et al. LEUKEMIA
- Profile of panobinostat and its potential for treatment in solid tumors: an update
- (2013) Madhurima Anne et al. OncoTargets and Therapy
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- (2012) Sally Clive et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma
- (2012) Jasmine Zain HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
- (2012) Massimo Offidani et al. LEUKEMIA & LYMPHOMA
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- (2012) Jeffrey L. Wolf et al. LEUKEMIA & LYMPHOMA
- A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
- (2011) S. J. Harrison et al. BLOOD
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer
- (2011) Geoffrey I. Shapiro et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
- (2011) Paul Hamberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
- (2011) Nan-Soon Wong et al. Pharmacogenetics and Genomics
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
- (2010) Shuhong Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- The DAC system and associations with multiple myeloma
- (2010) Enrique M. Ocio et al. INVESTIGATIONAL NEW DRUGS
- The potential role of epigenetic therapy in multiple myeloma
- (2009) Emma M. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
- (2009) P. N. Munster et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
- (2009) H Miles Prince et al. Future Oncology
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
- (2008) Peter Gimsing et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More